Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Bayer

In this podcast from members of PRECISION ONCOLOGY CONNECT and LUNG CONNECT, Assoc. Prof. Caterina Marchiò and Prof. Christian Rolfo discuss the detection and management of TRK fusion-positive lung cancer.


This podcast is also available on Castos, Spotify, Apple Podcasts and Google Podcasts.

This programme is supported by an Independent Educational Grant from Bayer

 In this podcast, NTRK CONNECT members Assoc. Prof. Caterina Marchiò (University of Turin, Italy) and Prof. Christian Rolfo (Center of Thoracic Oncology Tisch Cancer Institute Icahn School of Medicine at Mount Sinai, New York, USA) provide pathologist and medical oncologist perspectives about the detection and treatment of TRK fusion-positive lung cancer.

They discuss a number of techniques and strategies to identify this rare fusion in lung cancer patients, before going on to summarise the robust efficacy and safety data for both entrectinib and larotrectinib. Prof. Rolfo briefly covers second-generation therapies in clinical development and describes how liquid biopsy is emerging as a new technique to identify and monitor patients. They conclude by stressing the importance of the collaboration and communication between pathologists and oncologists to test for and identify TRK fusion-positive lung cancer patients.

Podcast Transcript

Caterina Marchió

Welcome everybody, today we are here for this podcast that is going to be covering lung cancer and the detection of NTRK gene fusion in lung cancer. I'm welcoming you here on behalf of the NTRK CONNECT group and the podcast will be dealt by a pathologist, I'm the pathologist, and I will be here with a medical oncologist. I'm Caterina Marchiò and I'm a molecular pathologist working at the University of Turin. I work at a cancer Institute, at The Candiolo Cancer Institute in Turin. Today I'm here with Christian Rolfo my co-chair medical oncologist.

Christian Rolfo

Hi Caterina, good afternoon and so I'm Christian Rolfo, I'm a thoracic oncologist at the Center of Thoracic Oncology at Mount Sinai in New York, Icahn School of Medicine and it's a pleasure to discuss today this important topic in lung cancer....

Prof. Rolfo is the Associate Director of Clinical Research at the Center for Thoracic Oncology, Tisch Cancer Institute in Mount Sinai System . In addition, he is Professor of Medicine at the Division of Hematology and Oncology at Icahn School of Medicine, Mount Sinai, New York, NY, USA. From April 2018 to May 2021 he was serving as Director of Thoracic Medical Oncology and Director of Early Clinical Trials at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (UMGCCC), in Baltimore, Maryland, USA. In addition, he was appointed Professor of Medicine at the Division of Oncology at Maryland University, School of Medicine. Prof. Rolfo is Medical Oncologist focused in Thoracic Oncology, Drug Development and Translational Oncology. From 2012 to March 2018 he was working as Director of the Phase I - Early Clinical Trials Unit, Director of the Clinical Trials Management Program at Antwerp University Hospital, and Senior Staff member of Thoracic Oncology Cluster at Antwerp University Hospital in Belgium. In addition he is Professor of Oncology at Antwerp University in the Center for Oncological Research (CORE) in Antwerp, Belgium, Professor Rolfo graduated with a degree in medicine from the National University of Córdoba, Argentina in 1996; he then studied at the University of Milan and the National Cancer Institute of Milan, Italy, receiving European Oncology Board certification in 2003, followed by Spanish Board Certification in Medical Oncology in 2007. He obtained a PhD and Doctor Europaeus in Clinical and Experimental Oncology Research cum laude from the University of Palermo, Italy in 2009 under the direction of Professor Rosell, and a Master of Business Health Administration from the Polytechnic University of Valencia, Spain in 2010. He worked as clinical researcher in the Spanish Lung Cancer Group in Mallorca, Spain for 8 years. He is actively working on drug development and Lung cancer & Mesothelioma treatment. His research is focused in molecular oncology and Immunotherapy in Thoracic Oncology and in a pan-tumoral approach, using new techniques in liquid biopsies, specifically in exosome isolation and circulating free tumour DNA. His group identify ALK translocation in exosomes in NSCLC patients, showed, for the first time, the videos of labeled EVs uptake by living lung cancer cells. He is currently working in the identification of new biomarkers involved in immunotherapy and TKI drug-resistance. In Drug development Prof. Rolfo contributed to the development of several compounds including Erlotinib, pharmacokinetics of Olaparib, Entrectinib among several drugs in early phase.

Prof. Christian Rolfo has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Archer Dx, AstraZeneca, BMS, Boston Pharmaceuticals, Blueprint, Eisai, Inivata, Guardant Health, MD Serono, Mirati, MSD, Novartis, Pfizer and Roche.

 

Dept. of Medical Sciences - University of Turin Pathology Unit, FPO-IRCCS Candiolo Cancer Institute, strada provinciale 142, 10060 Candiolo Caterina Marchiò, MD PhD, obtained her medical degree at The University of Turin graduating summa cum laude in 2004. She completed her PhD in 2008 after working in collaboration between the University of Turin and the Breakthrough Breast Cancer Research Centre at the Institute of Cancer Research in London between 2006 and 2008. Upon completion of the residency in Pathology at the University of Turin she visited as a Research Scholar the Department of Pathology at Memorial Sloan Kettering Cancer Centre in New York in 2014. She joined the faculty at the University of Turin as an Assistant Professor of pathology at the end of 2014 and she was appointed Associate Professor of Pathology in 2018. Between 2017 and 2018 she served as Visiting Professor at the Pathology Department of Institut Curie in Paris, as a Mayent-Rotschild grantee. Prof. Caterina Marchiò is a diagnostic and experimental pathologist at the Pathology Unit of FPO-IRCCS Candiolo Cancer Institute (University of Turin). Her routine diagnostic activity focuses on breast pathology and molecular diagnostics of solid tumors, including sign-out for in situ hybridization, DNA sequencing and RNA-based assays applied to diagnostics. Her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive carcinomas. A specific interest in HER2-equivocal breast cancer has been funded by the Italian Association of Cancer Research (AIRC), Regione Piemonte and the Ministry of University, Education and Research. She has also actively worked on the standardization of the preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens. She is part of the SPIDIA4P consortium, funded by the European Community (H2020-SC1-2016-2017, EU project 733112 – “SPIDIA4P - SPIDIA for Personalized Medicine).

Assoc. Prof. Caterina Marchiò has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Astrazeneca, Bayer, Roche and Daiichi Sankyo. 

Programme summary
Listen to the podcast now
Share this programme
This educational programme is supported by an Independent Medical Education Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
LUNG CONNECT

Meet the experts

Other programmes of interest

podcast Podcast
Oncology 
Perseverance in molecular testing in NSCLC pays off

Looking beyond the obvious mutations in non-small-cell lung cancer

Experts
Prof. Frédérique Penault-Llorca, Prof. Mark Socinski
  • download Downloadable
    Resources
  • clock 26 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ER+ advanced breast cancer: Highlights from EBCC-14 satellite symposium

Medical experts discuss current and upcoming treatment strategies to use after CDK4/6 inhibitors in patients with ER+/HER2- advanced breast cancer

Experts
Prof. Valentina Guarneri, Prof. Matteo Lambertini, Prof. Federico Rojo
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline.
interactive-patient-case Interactive patient case
Oncology 
TRK fusion-positive lung cancer: Diagnosis and treatment

Make decisions for your patient at two key stages in their journey

Experts
Prof. Fernando López-Ríos, Prof. Mark Socinski
  • clock 60 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer
conference-update Conference update
Oncology 
ESMO 2023: Lung cancer update

Experts discuss new lung cancer data at a meeting hosted by eChinaHealth and COR2ED

  • clock 43 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from This educational programme is supported by an Independent Medical Education Grant from SystImmune and BeiGene Europe.
other Other
Oncology 
Lung cancer survey: Patient views on biomarker testing

Share the survey with patients with lung cancer and their caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos
Endorsed by
LUNGevity
Lung Cancer Europe IASLC
The Israeli Lung Cancer Foundation ISLB
  • download Downloadable
    Resources
  • clock 2 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
podcast Podcast
Oncology 
Precision oncology approaches in lung cancer

Explore pre-analytical phase challenges and biomarker testing in lung cancer. Moderated by the Oncology Brothers.

Experts
Dr Bruna Pellini, Dr Semir Vranić, Oncology Brothers (Moderators)
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 25 MIN
  • calendar Mar 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.